Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma

Annals of Oncology

Volumn 9, Issue 5, 1998, Pages 511-518

  Cabanillas, F ^a   Rodriguez Diaz Pavon J ^a   Hagemeister, F B ^a   McLaughlin, P ^a   Rodriguez, M A ^a   Romaguera, J E ^a   Dong, K ^a   Moon, T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aggressive lymphomas; ATT; CHOP; Intermediate grade lymphomas; Prognostic factors

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOXANTRONE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; IMMUNOBLASTIC SARCOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCORING SYSTEM; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; LYMPHOMA, INTERMEDIATE-GRADE; LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC; MALE; MESNA; METHOTREXATE; METHYLPREDNISOLONE HEMISUCCINATE; MIDDLE AGED; MITOXANTRONE; PREDNISONE; PROGNOSIS; VINCRISTINE;

EID: 7144222752     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008214629544     Document Type: Article

References (28)

1. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328 (14): 1002-6.
2. Cabanillas F, Pathak S, Grant G et al. Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. Am J Med 1989; 87 (2): 167-72.
3. Shipp M. Prognostic factors in non-Hodgkin's lymphoma. Curr Opin Oncol 1992; 4 (5): 856-62.
4. Lopez-Guillermo A, Montserrat E, Reverter JC et al. Large-cell lymphoma: A study of prognostic factors and assessment of five recently proposed predictive systems. Leuk Lymph 1993; 10 (1-2): 101-9.
5. Freedman A. Expression and function of adhesion receptors on normal B cells and B-cell non-Hodgkin's lymphomas. Semin Hematol 1993; 30 (4): 318-28.
6. Pezzella F, Jones M, Ralfkiaer E. Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphomas. Br J Cancer 1992; 65: 87.
7. Seymour JF, Talpaz M, Cabanillas F et al. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995; 13: 575-82.
8. Coiffier BCG, Vose JM, Tilly H et al. Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol 1991; 9 (2): 211-9.
9. Slymen DJ, Miller TP, Lippman SM et al. Immunlogic factors predictive of clinical outcome in diffuse large-cell lymphoma. J Clin Oncol 1990; 8 (986): 1990.
10. Medeiros LJ, Picker LJ, Gelb AB et al. Numbers of host 'helper' T cells and proliferating cells predict survival in diffuse small-cell lymphomas. J Clin Oncol 1989; 7: 1099.
11. O'Keane JC, Mack C, Lynch E et al. Prognostic correlation of HLA-DR expression in large-cell lymphoma as determined by LN3 antibody staining. Cancer 1990; 66: 1147.
12. Horst E, Meijer CJLM, Radaszkiewicz T et al. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: Expression of a lymphocyte homing receptor (CD44). LFA-1 (CD11a/18) and ICAM-1 (CD54). Leukemia 1990; 4: 595.
13. Romaguera JE, Manning JT, Tornos CS et al. Long-term prognostic importance of primary Ki-1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large-cell lymphoma. Ann Oncol 1994; 5: 317-22.
14. Velasquez WS, Jagannath S, Tucker SL et al. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood 1989; 74 (2): 551-7.
15. Rodriguez MA, Cabanillas FC, Velazquez WS. Results of a salvage treatment program for relapsing lymphoma: MESNA/ ifosfamide, novantrone, and etoposide (MINE), consolidated with etoposide, solumedrol, high-dose arabinoside and cisplatinum (ESHAP). J Clin Oncol 1995; 13 (7): 1734-41.
16. Goldie J, Coldman A. A mathematical model relating the drug sensitivity of tumor to the spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-933.
17. The international non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329 (14): 987-95.
18. Rodriguez J, Cabanillas F, McLaughlin P et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the tumor score. Ann Oncol 1992; 3: 711-7.
19. Velasquez WS, McLaughlin P, Fuller LM et al. Intermediate grade lymphomas treated with cyclophosphamide doxorubicin vincristine- prednisone- bleomycin-alternated with cyclophosphamide-methotrexate etoposide dexamethasone. Cancer 1994; 73 (9): 2408-16.
20. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
21. Rodriguez J, Pugh WC, Cabanillas F. T-cell rich B-cell lymphoma. Blood 1993; 82 (5): 1586-9.
22. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 1992; 10: 334.
23. Verdonck L, van Putten WLJ, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 16: 1045-51.
24. Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896-903.
25. Levine AM. Lymphoma complicating immunodeficiency disorders. Ann Oncol 1994; 5 (Suppl 2): 29-36.
26. List AF, Spier CM, Miller TP, Grogan TM. Deficient tumor infiltrating T lymphocyte response in malignant lymphoma: Relationship to HLA expression and host immunocompetence. Leukemia 1993; 7: 398.
27. Miller TP, Lippman SM, Epier CM et al. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large-cell lymphoma. J Clin Invest 1988; 82: 370.
28. Mackall CL, Fleisher TA, Brown MR et al. Age, thymopoieisis and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332: 143-9.